From the Journals

Hemophilia adherence tied to perception of disease


 

FROM VOX SANGUINIS

More than half (56%) of adult patients with hemophilia are adherent to a prescribed prophylaxis regimen, but compliance appears less likely among patients who are having difficulty coping with pain or have a high conviction of disease.

Ana Torres-Ortuño, PhD, of the University of Murcia (Spain) and her colleagues performed a multicenter, cross-sectional descriptive study of 23 adult patients with severe hemophilia A or hemophilia B using various validated questionnaires that measured quality of life, disease perception, coping strategies, and treatment adherence.

Crystal/Wikimedia Commons/Creative Commons Attribution 2.0

The researchers found that complications and comorbidities made it more likely that hemophilia patients would be compliant with prophylaxis. Patients who experienced haemarthrosis with greater frequency had significantly greater adherence in terms of dosing (P less than .05), planning (P less than .05), and skipping (P less than .01). Similarly, patients with HIV infection were more adherent in terms of frequency of infusion than patients without infection.

The researchers also found significant correlations among all the psychosocial variables measured and adherence to prophylaxis. For instance, patients who had poorer quality of life related to managing their physical health, pain, and emotions showed poorer planning of their treatment. Patients who had difficulty remembering treatment had poorer quality of life related to pain and vitality, but they also had greater conviction of disease and hypochondriasis.

“Intervention programmes should be aimed more at changing barriers that patients and caregivers encounter when accepting diagnosis and how they can adapt their resources and skills to better take advantage of the progress made in treatments,” the researchers wrote.

The study was supported by a grant from Pfizer. The researchers reported having no financial disclosures.

SOURCE: Torres-Ortuño A et al. Vox Sang. 2018 May 24. doi: 10.1111/vox.12669.

Recommended Reading

FDA approves Doptelet for liver disease patients undergoing procedures
MDedge Hematology and Oncology
Tailored hemophilia prophylaxis could cut costs
MDedge Hematology and Oncology
Emicizumab gets priority review for hemophilia A without inhibitors
MDedge Hematology and Oncology
Emicizumab granted priority review for hemophilia A without inhibitors
MDedge Hematology and Oncology
Perioperative rVWF alone sufficient for some VWD patients
MDedge Hematology and Oncology
Emicizumab controls bleeding regardless of inhibitors
MDedge Hematology and Oncology
Gene therapy reduces ABR, AIR in hemophilia B
MDedge Hematology and Oncology
Therapy can extend half-life of FVIII
MDedge Hematology and Oncology
N9-GP has better PK profile than rFIXFc, team says
MDedge Hematology and Oncology
Emicizumab reduces bleeding in hemophilia A
MDedge Hematology and Oncology